Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Guidant Files Lawsuit To Force J&J To Complete Acquisition

This article was originally published in The Gray Sheet

  • News

Executive Summary

Guidant filed a civil lawsuit against Johnson & Johnson on Nov. 7 in an effort to force the healthcare giant to complete its proposed $25.4 bil. acquisition

You may also be interested in...



J&J Salvages Deal With Guidant: $4 Bil. Shaved Off Purchase Price

Johnson & Johnson's renegotiated deal to acquire Guidant for $21.5 bil. will make medical devices the firm's largest business segment once the merger closes

J&J Salvages Deal With Guidant: $4 Bil. Shaved Off Purchase Price

Johnson & Johnson's renegotiated deal to acquire Guidant for $21.5 bil. will make medical devices the firm's largest business segment once the merger closes

As J&J Backs Away From The Altar, Guidant Asks Court For Shotgun Wedding

Johnson & Johnson is likely to point to Guidant's weak third quarter sales and earnings as evidence that recent recalls have had a "material adverse effect" on Guidant

Table

View full table

Related Content

Medtech Insight
Tags:
Latest Headlines

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

See All
UsernamePublicRestriction

Register

MT022865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By